Work

AML-262: Ivosidenib (IVO) Prior to Hematopoietic Cell Transplant (HCT) for Patients with IDH1-Mutant Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) Who Cannot Tolerate Intensive Chemotherapy (IC)

Year: 2020

Type: conference-abstract

Source: Clinical Lymphoma Myeloma & Leukemia

DOI: 10.1016/s2152-2650(20)30745-x

Authors: Courtney D DiNardo, Eytan M Stein, Arnaud Pigneux, Jessica K Altman, Robert Collins, Harry P Erba, Justin M Watts, Geoffrey L Uy, Bin Wu, Sung Choe, Stephanie M Kapsalis, Hua Liu, Thomas Winkler, Gail J Roboz, Stéphane de Botton

Institutions: The University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, Centre Hospitalier Universitaire de Bordeaux, Northwestern University, The University of Texas Southwestern Medical Center, University of Alabama at Birmingham, University of Miami, Sylvester Comprehensive Cancer Center, Washington University in St. Louis, Agios Pharmaceuticals (United States), NewYork–Presbyterian Hospital, Weill Cornell Medicine, Institut Gustave Roussy

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3111567082

Cites:

Cited by:

Related to: 10